Blood Tests to Study Biomarkers in Advanced Thyroid Cancer
Studies blood samples from adults with advanced thyroid cancer to guide treatment choices.
Plain-language title generated from the registry record
Registry title: Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Azienda Ospedaliero universitaria BolognaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06863805
- Record updated
- 7 March 2025
- Original description
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choicesRead full original descriptionShow less
Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices
Inclusion: Signed written informed consent,; Adult (≥18 years) male or female patients; Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review,; well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy,; Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue,; Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA).
Exclusion: Patients already receiving previous lines of systemic therapy,; Patients not eligible for systemic therapy.